Results for "ivonescimab"

Shares of Summit Therapeutics jumped significantly after the company reported positive developments regarding its experimental drug ivonescimab.

Summit Therapeutics has outlined November 14 as the FDA PDUFA date for its ivonescimab Biologics License Application (BLA) and plans for HARMONi-3 PFS in the second half of 2026.

New clinical trial results indicate that drugs from Akeso and Lilly are showing promise in treating lung cancer. Akeso's drug, ivonescimab, has announced better-than-expected clinical results for a type of lung cancer, potentially expanding its application, while Lilly's Retevmo reduced the risk of recurrence in a late-stage trial.

Clinical trial results indicate that Summit Therapeutics’ investigational drug ivonescimab meets key secondary endpoints for overall survival in non-small cell lung cancer patients. The promising interim data positions the treatment as a potential new standard in first-line therapy.

Summit (SMMT) reported positive Phase III overall survival data for its drug Ivonescimab in patients with advanced Non-Small Cell Lung Cancer (NSCLC).

Summit Therapeutics Inc. is concentrating its efforts on the clinical trial of Ivonescimab, a drug being developed for the treatment of non-small cell lung cancer.

An interim analysis of the Phase III HARMONi-2 study reveals that ivonescimab meets key secondary endpoints for overall survival, demonstrating clinically meaningful benefits compared to pembrolizumab in first-line PD-L1-positive non-small cell lung cancer patients.

A highly anticipated study revealed that the experimental lung-cancer drug ivonescimab reduced the risk of death by 34% compared with another drug, though investors' reaction was muted.